1. FABP7: A Potential Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma.
- Author
-
Panwoon C, Seubwai W, Thanee M, and Sangkhamanon S
- Subjects
- Humans, Male, Female, Prognosis, Middle Aged, Aged, Neoplasm Staging, Adult, Immunohistochemistry, Aged, 80 and over, Fatty Acid-Binding Proteins genetics, Fatty Acid-Binding Proteins metabolism, Gene Expression Regulation, Neoplastic, Tumor Suppressor Proteins, Carcinoma, Renal Cell diagnosis, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell pathology, Carcinoma, Renal Cell metabolism, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Fatty Acid-Binding Protein 7 metabolism, Fatty Acid-Binding Protein 7 genetics, Kidney Neoplasms diagnosis, Kidney Neoplasms pathology, Kidney Neoplasms genetics, Kidney Neoplasms metabolism
- Abstract
Background/aim: Renal cell carcinoma (RCC) is highly heterogeneous, with distinct patient management between clear cell RCC (ccRCC) and non-ccRCC groups. Previous bioinformatics and machine learning techniques identified fatty acid binding protein 7 (FABP7) as a potential ccRCC biomarker. However, FABP7 expression studies between ccRCC and non-ccRCC were incomplete. This study aimed to assess FABP7 as a biomarker for distinguishing between ccRCC and non-ccRCC tissue samples., Patients and Methods: FABP7 expression was evaluated via immunohistochemical staining in 58 RCC cases, including 43 ccRCC and 15 non-ccRCC cases. Staining results were interpreted using H-scores; scores above the cut-off were deemed positive. The correlation between FABP7 expression and clinicopathological RCC features was investigated., Results: FABP7 positivity was 48.8% in ccRCC and only 13.3% in non-ccRCC cases, with weak positivity in non-ccRCC tissues. FABP7 expression significantly differed between ccRCC and non-ccRCC (p<0.05). This finding was confirmed in a TCGA dataset. However, FABP7 expression was not correlated with other RCC clinicopathological features in our dataset. TCGA results linked FABP7 expression to tumor stage and disease-free survival in patients with ccRCC., Conclusion: This study preliminarily evaluated FABP7 as a differential diagnostic biomarker in RCC subtyping, showing higher expression in ccRCC than non-ccRCC. FABP7 may serve as a potential diagnostic and prognostic biomarker for ccRCC., (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF